Tags

Type your tag names separated by a space and hit enter

Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents.
Atten Defic Hyperact Disord 2012; 4(4):199-204AD

Abstract

The aim of this study was to assess baseline levels and changes in plasma fatty acid profiles in children and adolescents with ADHD, in a placebo-controlled study with Omega 3/6 supplementation, and to compare with treatment response. Seventy-five children and adolescents aged 8-18 years with DSM-IV ADHD were randomized to 3 months of Omega 3/6 (Equazen eye q) or placebo, followed by 3 months of open phase Omega 3/6 for all. n-3, n-6, n-6/n-3 ratio, EPA and DHA in plasma were measured at baseline, 3 and 6 months. Subjects with more than 25 % reduction in ADHD symptoms were classified as responders. At baseline, no significant differences in mean fatty acid levels were seen across active/placebo groups or responder/non-responder groups. The 0-3 month changes in all parameters were significantly greater in the active group (p < 0.01). Compared to non-responders, the 6-month responders had significantly greater n-3 increase at 3 months and decrease in n-6/n-3 ratio at 3 and 6 months (p < 0.05). Omega 3/6 supplementation had a clear impact on fatty acid composition of plasma phosphatidyl choline in active versus placebo group, and the fatty acid changes appear to be associated with treatment response. The most pronounced and long-lasting changes for treatment responders compared to non-responders were in the n-6/n-3 ratio.

Authors+Show Affiliations

The Gillberg Neuropsychiatry Centre at the Sahlgrenska Academy, Göteborg University, Kungsgatan, Sweden. johnson.mats@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22753087

Citation

Johnson, Mats, et al. "Fatty Acids in ADHD: Plasma Profiles in a Placebo-controlled Study of Omega 3/6 Fatty Acids in Children and Adolescents." Attention Deficit and Hyperactivity Disorders, vol. 4, no. 4, 2012, pp. 199-204.
Johnson M, Månsson JE, Ostlund S, et al. Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents. Atten Defic Hyperact Disord. 2012;4(4):199-204.
Johnson, M., Månsson, J. E., Ostlund, S., Fransson, G., Areskoug, B., Hjalmarsson, K., ... Gillberg, C. (2012). Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents. Attention Deficit and Hyperactivity Disorders, 4(4), pp. 199-204. doi:10.1007/s12402-012-0084-4.
Johnson M, et al. Fatty Acids in ADHD: Plasma Profiles in a Placebo-controlled Study of Omega 3/6 Fatty Acids in Children and Adolescents. Atten Defic Hyperact Disord. 2012;4(4):199-204. PubMed PMID: 22753087.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents. AU - Johnson,Mats, AU - Månsson,Jan-Eric, AU - Ostlund,Sven, AU - Fransson,Gunnar, AU - Areskoug,Björn, AU - Hjalmarsson,Kerstin, AU - Landgren,Magnus, AU - Kadesjö,Björn, AU - Gillberg,Christopher, Y1 - 2012/07/03/ PY - 2012/02/10/received PY - 2012/06/18/accepted PY - 2012/7/4/entrez PY - 2012/7/4/pubmed PY - 2013/5/3/medline SP - 199 EP - 204 JF - Attention deficit and hyperactivity disorders JO - Atten Defic Hyperact Disord VL - 4 IS - 4 N2 - The aim of this study was to assess baseline levels and changes in plasma fatty acid profiles in children and adolescents with ADHD, in a placebo-controlled study with Omega 3/6 supplementation, and to compare with treatment response. Seventy-five children and adolescents aged 8-18 years with DSM-IV ADHD were randomized to 3 months of Omega 3/6 (Equazen eye q) or placebo, followed by 3 months of open phase Omega 3/6 for all. n-3, n-6, n-6/n-3 ratio, EPA and DHA in plasma were measured at baseline, 3 and 6 months. Subjects with more than 25 % reduction in ADHD symptoms were classified as responders. At baseline, no significant differences in mean fatty acid levels were seen across active/placebo groups or responder/non-responder groups. The 0-3 month changes in all parameters were significantly greater in the active group (p < 0.01). Compared to non-responders, the 6-month responders had significantly greater n-3 increase at 3 months and decrease in n-6/n-3 ratio at 3 and 6 months (p < 0.05). Omega 3/6 supplementation had a clear impact on fatty acid composition of plasma phosphatidyl choline in active versus placebo group, and the fatty acid changes appear to be associated with treatment response. The most pronounced and long-lasting changes for treatment responders compared to non-responders were in the n-6/n-3 ratio. SN - 1866-6647 UR - https://www.unboundmedicine.com/medline/citation/22753087/Fatty_acids_in_ADHD:_plasma_profiles_in_a_placebo_controlled_study_of_Omega_3/6_fatty_acids_in_children_and_adolescents_ L2 - https://dx.doi.org/10.1007/s12402-012-0084-4 DB - PRIME DP - Unbound Medicine ER -